Effect of neoadjuvant chemotherapy on gastric cancer based on FOLFOX7 or XELOX
10.3760/cma.j.issn.1673-4904.2013.07.009
- VernacularTitle:FOLFOX7或XELOX方案新辅助化疗治疗胃癌的疗效研究
- Author:
Shidong HE
;
Tuming ZHONG
;
Jianfang JI
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Chemotherapy,adjuvant;
Effectiveness studies
- From:
Chinese Journal of Postgraduates of Medicine
2013;(7):27-29
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of neoadjuvant chemotherapy on gastric cancer based on FOLFOX7 or XELOX,so as to achieve evidence of clinical practice.Methods From January 2005 to June 2010,a retrospective analysis was performed for those patients with gastric cancer and underwent surgery.The patients were divided into neoadjuvant chemotherapy group and conventional chemotherapy group according to the chemotherapy method.The clinical efficacy,Ro resection rate and survival rate were evaluated in two groups.Results A total of 185 cases were included in neoadjuvant chemotherapy group (FOLFOX7 or XELOX,113 cases) and conventional chemotherapy group (72 cases).There was no significant difference in general status between two groups (P ＞ 0.05).Complete remission was in 48 cases,partial remission was in 51 cases,stable was in 14 cases,progression of disease was in 0 case in neoadjuvant chemotherapy group,and the effective rate was 87.6％ (99/113).Complete remission was in 30 cases,partial remission was in 25 cases,stable was in 15 cases,progression of disease was in 2 cases in conventional chemotherapy group,and the effective rate was 76.4％(55/72).There was significant difference in the effective rate between two groups (P＜ 0.05).The R0 resection rate in neoadjuvant chemotherapy group was higher than that in conventional chemotherapy group [60.2％ (68/113) vs.38.9％ (28/72)],and there was significant difference between two groups (P＜ 0.01).There was no significant difference in survival rate between two groups (P ＞ 0.05).Conclusion Neoadjuvant chemotherapy can reduce the tumor stage and improve the R0 resection rate,but has no obvious advantage in improving the survival rate during follow-up period.
